Predictors of hemorrhagic transformation in symptomatic recurrent acute cerebral ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator

Background Hemorrhagic transformation (HT) is a challenging complication of thrombolytic therapy that can lead to increased morbidity and mortality in recurrent ischemic stroke. Aim The study aimed to identify predictors of HT in recurrent symptomatic acute ischemic stroke (AIS) patients treated with intravenous thrombolysis. Patients and methods Forty-three patients with recurrent symptomatic AIS were recruited, and 10 of them developed HT. All patients underwent history taking and clinical examination, including Glasgow Coma Score and National Institute of Health Stroke Scale (NIHSS), Fazekas score, and modified Rankin scale, as well as radiological investigations, cardiac evaluation, and laboratory investigation [routine laboratories, neutrophil–lymphocyte ratio (NLR), C-reactive protein (CRP)-to-albumin ratio (CAR), international normalized ratio (INR), prothrombin time (PT), and fibrinogen level]. Outcome was assessed via clinical examination, NIHSS, and modified Rankin scale. Results Recurrent AIS patients with HT represented 23.2% of our sample of patients while symptomatic intracranial hemorrhage represented 13.9%. HT group had significant rates of atrial fibrillation, diabetes mellitus, hypertension, valvular heart disease, higher blood pressure, random blood sugar, Fazekas score, and NIHSS score. Most of HT patients were on anticoagulants for previous stroke. Most cases in the HT group received i.v. thrombolytic as treatment for their previous stroke. They also had increased NLR, high CAR, INR, PT, and low fibrinogen level, previous thrombolytic therapy, and low Alberta stroke program early non-contrast CT score. Conclusion HT in recurrent AIS patients receiving recombinant tissue plasminogen activator was associated with higher INR, NLR, PT, NIHSS, Fazekas score, CAR, lower fibrinogen, previous thrombolytic therapy, and low Alberta stroke program early non-contrast CT score.

Authors

Institutions

Publication Details

Journal
Tanta Medical Journal
Published
2026-01-01
DOI
https://doi.org/10.4103/tmj.tmj_56_25
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predictors of hemorrhagic transformation in symptomatic recurrent acute cerebral ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator

Osama A. Ragab, Ayman M. Al-Malt, Wael Fadel, Mohamed M. Seleem
Tanta Medical Journal
Acute Ischemic Stroke Management
article

Predictors of hemorrhagic transformation in symptomatic recurrent acute cerebral ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator

Osama A. Ragab, Ayman M. Al-Malt, Wael Fadel, Mohamed M. Seleem
article en

Abstract

Background Hemorrhagic transformation (HT) is a challenging complication of thrombolytic therapy that can lead to increased morbidity and mortality in recurrent ischemic stroke. Aim The study aimed to identify predictors of HT in recurrent symptomatic acute ischemic stroke (AIS) patients treated with intravenous thrombolysis. Patients and methods Forty-three patients with recurrent symptomatic AIS were recruited, and 10 of them developed HT. All patients underwent history taking and clinical examination, including Glasgow Coma Score and National Institute of Health Stroke Scale (NIHSS), Fazekas score, and modified Rankin scale, as well as radiological investigations, cardiac evaluation, and laboratory investigation [routine laboratories, neutrophil–lymphocyte ratio (NLR), C-reactive protein (CRP)-to-albumin ratio (CAR), international normalized ratio (INR), prothrombin time (PT), and fibrinogen level]. Outcome was assessed via clinical examination, NIHSS, and modified Rankin scale. Results Recurrent AIS patients with HT represented 23.2% of our sample of patients while symptomatic intracranial hemorrhage represented 13.9%. HT group had significant rates of atrial fibrillation, diabetes mellitus, hypertension, valvular heart disease, higher blood pressure, random blood sugar, Fazekas score, and NIHSS score. Most of HT patients were on anticoagulants for previous stroke. Most cases in the HT group received i.v. thrombolytic as treatment for their previous stroke. They also had increased NLR, high CAR, INR, PT, and low fibrinogen level, previous thrombolytic therapy, and low Alberta stroke program early non-contrast CT score. Conclusion HT in recurrent AIS patients receiving recombinant tissue plasminogen activator was associated with higher INR, NLR, PT, NIHSS, Fazekas score, CAR, lower fibrinogen, previous thrombolytic therapy, and low Alberta stroke program early non-contrast CT score.

Tanta Medical JournalVol. 54(1)
Tanta University (EG)
Good health and well-being
Openalex Percentile: Top 96%
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.